Nama's AI scorecard currently rates LivaNova Buy (6.3 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is LIVN's P/E ratio?

LivaNova trades at a trailing price-to-earnings ratio of 20.8.

When does LIVN report earnings?

LivaNova's next scheduled report is on Feb 24, 2027. Analysts expect EPS of $1.06.

What is the LIVN price target?

The median analyst price target from 11 analysts is $93.00, with a range of $75.00 – $105.00.

Is LIVN Shariah compliant?

Nama's AAOIFI-style screen reads LivaNova as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.

Nama Insights

LivaNova (LIVN)

Healthcare · Medical Devices · NASDAQ

LivaNova (LIVN) is a Healthcare company in the Medical Devices industry. It has a market capitalization of $4.96B, a trailing price-to-earnings ratio of 20.8 and a free-cash-flow yield of 3.5%. Over the most recent reported fiscal year, revenue grew 10.7% and free cash flow per share grew 27.7%. Nama's AI scorecard rates it Buy, 6.3 out of 10. On 12-month momentum it ranks in the leading band of its market.

AI scorecard

Buy · 6.3/10

Positive, at the low end of Buy. As of Nov 7, 2026.

Momentum

Leading · +53.2% over 12 months ex. last

Top 20% of its market on the past year's steady rise.

Shariah screen

Shariah Compliant

Passes our debt, cash and income screen; not a scholar's ruling.

Off its high

-9.4%

How far the last close sits under the highest price of the past five years.

Market cap	$4.96B
Trailing P/E	20.8
Price / book	3.7
Price / sales	3.4
FCF yield	3.5%
Dividend yield	—
Gross margin	68.1%
Operating margin	12.7%
Net margin	12.8%
Revenue growth (YoY)	+10.7%
Revenue growth (3-yr annual)	+10.8%
EPS growth (YoY)	+15.7%
FCF/share growth (YoY)	+27.7%
Beta	0.9
Exchange	NASDAQ
Sector	Healthcare
Industry	Medical Devices

LIVN earnings

Next report: Feb 24, 2027 (Q4 2026, EPS estimate $1.06). Beat the EPS estimate in 4 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Nov 4, 2026	$1.23	$1.06	+16.0%	$393.15M
Q2 2026	Aug 5, 2026	$1.26	$1.09	+15.6%	$390.59M
Q1 2026	May 6, 2026	$0.98	$0.90	+8.9%	$362.26M
Q4 2025	Feb 25, 2026	$0.86	$0.81	+6.2%	$360.92M

LIVN analyst price target

Median target $93.00 from 11 analysts, ranging $75.00 – $105.00.

Medical Devices peers

Ticker	Company	Market cap	P/E
ABT	Abbott Laboratories	$190.39B	20.4
MDT	Medtronic	$130.22B	17.8
SYK	Stryker	$124.06B	22.8
BSX	Boston Scientific	$61.96B	13.4
EW	Edwards Lifesciences	$58.73B	34.7
GEHC	GE HealthCare Technologies	$37.25B	16.8
PHG	Koninklijke Philips	$29.67B	15.2
DXCM	DexCom	$29.62B	29.7

Explore live LIVN data on Nama Insights →

LIVN FAQ

Is LIVN a buy?: Nama's AI scorecard currently rates LivaNova Buy (6.3 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is LIVN's P/E ratio?: LivaNova trades at a trailing price-to-earnings ratio of 20.8.
When does LIVN report earnings?: LivaNova's next scheduled report is on Feb 24, 2027. Analysts expect EPS of $1.06.
What is the LIVN price target?: The median analyst price target from 11 analysts is $93.00, with a range of $75.00 – $105.00.
Is LIVN Shariah compliant?: Nama's AAOIFI-style screen reads LivaNova as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.